Bringing the fundamentals into focus…
Back to 4D Molecular Therapeutics, Inc.
How 4D Molecular Therapeutics, Inc. stacks up
FDMT · against 1,327 other Healthcare companies
Overall
43/ 100
Below the middle of the pack.
Ranked #841 of 1,328 · scores higher than 35% of peers
Bars: peers in each 10-point band of the overall score233 peers with an overall score of 40–49, including FDMT · Click a bar to see the companies
The four scores behind it
Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)Ranking by overall score
Top 5 and the companies ranked around FDMT| Rank | Company | Market cap | Overall | Valuation | Growth | Profitability | Risk |
|---|---|---|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | 100 | 0 / 2 | ||
| 2 | 595M USD | 97 | 96 | 98 | 99 | 0 / 2 | |
| 2 | 261M USD | 97 | 93 | — | 98 | 0 / 2 | |
| 4 | 2.1B USD | 96 | 96 | 99 | 93 | 0 / 2 | |
| 4 | 15.6B DKK (≈$2.3B) | 96 | 96 | 99 | 96 | 0 / 2 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score